Positions for Neurocrine Biosciences Inc (NASDAQ:NBIX)

“Big money sentiment for Neurocrine Biosciences Inc (NASDAQ:NBIX) in Q4 2018 decreased to 0.99, according to SEC filings. So its down -0.34, from 2018Q3’s 1.33. 142 funds started new and increased stock positions, while 144 decreased and sold their equity positions in Neurocrine Biosciences Inc so the sentiment has dropped. These funds own 86.79 million shares, that’s up from 86.00 million shares in 2018Q3. Funds holding Neurocrine Biosciences Inc in top 10 was flat from 4 to 4 for the same number . In total 57 funds closed positions, 87 reduced and 87 increased. Also 55 funds bought new Neurocrine Biosciences Inc stakes.

Largest Neurocrine Biosciences Inc Investors

As of Q4 2018 Perceptive Advisors Llc has 12% invested in Neurocrine Biosciences Inc. As of Q4 2018, 3.34 million shares of Neurocrine Biosciences Inc are owned by Bb Biotech Ag. Further, Birchview Capital Lp reported 55,000 shares in Neurocrine Biosciences Inc equivalent to 3.72% of its fund portfolio. The Maryland-based fund Rock Springs Capital Management Lp have invested about 2.66% of the fund’s stock portfolio in Neurocrine Biosciences Inc. The New York-based fund Healthcor Management L.P. holds 793,955 shares or 2.48% of their fund portfolio.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally.The company has $8.29 billion market cap. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease.The P/E ratio is 414.86. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Ticker’s shares touched $91.27 during the last trading session after 3.79% change.Currently Neurocrine Biosciences, Inc. is downtrending after 6.23% change in last April 7, 2018. NBIX has 605,548 shares volume. NBIX underperformed by 10.60% the S&P 500.

On April, 29 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s earnings report is anticipated by WallStreet, according to RTT. The EPS diference is $0.45 or 95.74 % down from last years number. Previous year: $-0.47; Analysts forcast: $-0.92. Analysts at Wall Street see Neurocrine Biosciences, Inc.’s -584.21 % negative EPS growth compared to $0.19 EPS for previous quarter.

Rhumbline Advisers has 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 97,337 shs. Assetmark Inc has 28 shs. Mackay Shields holds 17,772 shs. Sumitomo Life Ins reported 0.1% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Pennsylvania-based Vanguard has invested 0.03% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Neuberger Berman Gp Ltd reported 157,947 shs. Prudential Fin invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Eaton Vance Mngmt invested 0.02% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Moreover, Geode Cap Mgmt Lc has 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). 23,354 were reported by Tiverton Asset Mgmt Lc. Victory Cap holds 0.1% or 553,185 shs. Quantbot Techs Lp reported 0% stake. Swiss Commercial Bank reported 0.01% of its capital in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Steinberg Global Asset Management invested in 0.19% or 15,511 shs. Stevens Capital Mgmt Lp has 3,572 shs.

Neurocrine Biosciences, Inc. had 24 selling transactions and 0 insider buys since October 29, 2018. This’s net activity of $15.26 million. Gano Kyle also sold $63,673 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shs. Bozigian Haig P. sold $3.99 million worth of stock or 36,295 shs. $589,237 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by POPS RICHARD F on Monday, October 29. On Wednesday, February 6 $66,063 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by Lippoldt Darin. BENEVICH ERIC sold $119,427 worth of stock. Shares for $671,216 were sold by GORMAN KEVIN CHARLES on Monday, February 4.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

In total 9 analysts cover Neurocrine Biosciences (NASDAQ:NBIX). “Buy” rating has 6, “Sell” are 0, while 3 are “Hold”. 67% are bullish. 12 are the (NASDAQ:NBIX)’s analyst reports since November 6, 2018 according to StockzIntelligence Inc. On Tuesday, March 12 the stock has “Hold” rating by Leerink Swann. In Tuesday, March 12 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Wednesday, January 23 the firm earned “Neutral” rating by JP Morgan. On Wednesday, March 13 H.C. Wainwright maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) with “Buy” rating. On Thursday, January 24 the firm has “Hold” rating by Needham given. On Wednesday, March 13 the firm earned “Buy” rating by Cowen & Co. The company rating was maintained by Morgan Stanley on Tuesday, November 6.

For more Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news released briefly go to: Nasdaq.com, Seekingalpha.com, Fool.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Notable ETF Outflow Detected – XBI, LGND, IMMU, NBIX – Nasdaq” released on March 27, 2019, “Neurocrine Bio’s NBI-74788 shows positive action in mid-stage adrenal hyperplasia study – Seeking Alpha” on March 12, 2019, “1 Biotech That Biogen Should Buy … but Probably Won’t – The Motley Fool” with a publish date: April 04, 2019, “Noteworthy Thursday Option Activity: NBIX, CRUS, C – Nasdaq” and the last “Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology – Nasdaq” with publication date: March 28, 2019.